Drug Discovery

#Academic #AI / data analytics / healthtech / informatics #Automation / robotics #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #RNA #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Dotmatics acquires BioBright to accelerate laboratory data automation

25 June 2020 Dotmatics has agreed to acquire BioBright, an expert in automating the flow of data from laboratory instruments to a secure cloud. BioBright’s solutions enable scientists to automate the collection of data from in-house and externally networked sources, and then standardise and analyse crucial experimental data… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Precision medicine #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

PrecisionLife identifies 68 genes associated with risk of severe COVID-19

Scientists from AI precision medicine company, PrecisionLife, have found 68 genes associated with risk of developing severe COVID-19 by using its proprietary AI-enabled precision medicine platform to analyse the genomes of 929 patients from the UK Biobank who had a severe response to SARS-CoV-2. Prior to an effective… Read More

#Covid-19 #News

#Analysis #Business #Drug development #Drug discovery #Lead discovery

Applied Photophysics and Fluorescence Innovations make protein stability systems

24 June 2020 Image: Sincerely Media Applied Photophysics (APP) and Fluorescence Innovations (FI) have entered into a joint venture agreement to develop and produce protein stability systems for leading researchers and industries around the globe. The two firms said they will be equal partners in the new initiative. Read More

#News

#AI / data analytics / healthtech / informatics #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Lead discovery #Lead optimisation #Regulatory #Target validation

Avacta positive on evaluation of COVID-19 test strips

Avacta Group has announced that the first Affimer-based rapid test strips to detect SARS-COV-2 spike protein have been developed and evaluated by partners at Cytiva (formerly GE Healthcare Life Sciences) and show positive initial performance data. In mid-May Avacta provided Affimer reagents that are specific to the SARS-COV-2… Read More

#Covid-19 #News

#Biologics / Biotechnology #Business #Clinical trials #Drug development #Drug discovery #High Content Screening #Imaging #Immunology / Virology & Vaccines #Lead discovery #Precision medicine #RNA

Symbiosis to manufacture COVID-19 vaccine for clinical trials

Symbiosis Pharmaceutical Services has signed a supply agreement with AstraZeneca for sterile manufacture of the COVID-19 recombinant adenovirus vaccine known as AZD1222 for AstraZeneca sponsored clinical trials. Under the agreement, Symbiosis will provide AstraZeneca fast-track access to sterile vaccine drug product manufacturing capacity for clinical trial… Read More

#Covid-19 #News

#Business #Cell therapy #Clinical trials #Drug development #Oncology #Preclinical #Stem cells

Scenic Biotech awarded fund to progress immuno-oncology program

23 June 2020 Image: Austin Distel The Innovation Credit is awarded by the Dutch government through its agency RVO of the Ministry of Economic Affairs and Climate Policy and is aimed at the development of promising and challenging innovations. The €3.1million fund will support the preclinical… Read More

#News

#Biologics / Biotechnology #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Immunology #Microbiology #RNA #Stem cells #System biology

Taconic Biosciences to distribute critical COVID-19 mouse model

Taconic Biosciences has announced an exclusive agreement with the University of Texas Medical Branch at Galveston (UTMB) to distribute humanised ACE2 mice for coronavirus research. The SARS-CoV-2 virus, which causes COVID-19, uses the ACE2 receptor to enter cells, causing infection. Due to differences between the mouse and human… Read More

#Covid-19 #News

#Academic #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Epidarex announces £100 million UK venture fund to back life science firms

22 June 2020 Epidarex Capital, an international finance firm, has launched a £102 million fund in Edinburgh to invest in emerging life sciences businesses. The fund will build new life science companies using world-class research and innovation from emerging hubs across the UK, including university spinouts. Typical initial investments… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Business #Computational chemistry #Drug development #Gene editing #Genomics #Immunology #RNA #Screening #System biology #Systems biology

Still time to register for SLAS Transformed 2020

22 June 2020 SLAS Transformed is an interactive event focused on omics, synthetic biology and genome editing along with applicable implications for the current pandemic. The two-day event runs from 23-24 June 2020, offering 30-minute scientific research presentations, live exhibitor presentations and one-on-one networking sessions. It will span multiple… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Business #Cell therapy #Cellular assays #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Oncology #Regulatory #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

CatalYm to present data on immunotherapy of cancer at AACR Annual Meeting

19 June 2020 CatalYm will be presenting two abstracts identifying a novel immunoregulatory role for Growth-and-Differentiation Factor 15 (GDF-15) and its effective neutralisation by CTL-002 antibody in cancer at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on 22-24 June. Tumor-derived GDF-15 suppresses T-lymphocyte recruitment… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Pharmacology #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Dexamethasone identified as potential for treatment of COVID-19 ten weeks ago

AI VIVO, a company combining systems pharmacology and artificial intelligence (AI) to accelerate drug discovery, has announced that its platform identified dexamethasoneas having high potential for the treatment of COVID-19 in April 2020. AI VIVO, a company combining systems pharmacology and artificial intelligence (AI) to accelerate… Read More

#Covid-19 #News

#Biologics / Biotechnology #Cell therapy #Cellular assays #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Immunology #Stem cells

Avacta collaboration offers update on Affimer therapy for COVID-19

Avacta Group, in collaboration with the Centre for Virus Research at the University of Glasgow, has shown that Affimer reagents which bind to the SARS-COV-2 virus spike protein, prevent infection of human cells by a SARS-COV-2 model virus and therefore provide a potential therapy for COVID-19 infection. Avacta… Read More

#Covid-19 #News

#Biologics / Biotechnology #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Immunology / Virology & Vaccines #RNA

Cobra Biologics signs manufacture agreement with AstraZeneca for COVID-19 vaccine candidate

Cobra Biologics will provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19. Cobra Biologics, part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, has signed a supply agreement with AstraZeneca UK to provide GMP manufacture of the adenovirus vector-based… Read More

#Covid-19 #News

#Drug development #Drug discovery #Drug targets

Ubiquigent continues drug discovery collaboration with Bristol Myers Squibb

17 June 2020 Ubiquigent is continuing its collaboration with Bristol Myers Squibb. The collaboration, originally between Ubiquigent and Celgene, will allow Bristol Myers Squibb to capitalise on Ubiquigent’s deubiquitylase (DUB) enzyme inhibitor drug discovery platform. The central role of ubiquitylation in diverse cellular processes, including protein degradation, makes… Read More

#News

#Academic #Biomarkers #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Molecular medicine #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Mobidiag receives second tranche of financing from European Investment Bank

17 June 2020 This is the second tranche of growth capital loan signed with the European Investment Bank in May 2019. The new funds will be used for the development, manufacture and commercialisation of in vitro diagnostics for infectious diseases Mobidiag, a revenue generating, molecular diagnostics company with… Read More

#News